AMIDEX Cancer Innovation & Healthcare
970 Rittenhouse Road Willow Grove, PA 19090
Map
Phone: 888-876-3566
| Category: | Health | | Fund Family: | AMIDEX | | Net Assets: | 810.00K | | Year-to-Date Return: | 2.73% | | Yield: | 0.00% | | Morningstar Rating: |  | | Fund Inception Date: | 01-Nov-01 |
|
Gadi Beer
Lead Manager since
01-Nov-01 | | | Beer is the chief operating officer of Index Investments LLC. He has served as research analyst and vice president since 1999. |
| Min Initial Investment: | $500 | | Min Initial Investment, IRA: | $500 | | Min Initial Investment, AIP: | $500 | | Min Subsequent Investment: | $205 | | Min Subsequent Investment, IRA: | $250 | | Min Subsequent Investment, AIP: | $250 |
|
| |
| The investment seeks long-term growth of capital. The fund usually invests at least 95% of assets in common stocks of companies listed on the AMIDEX-TM- Cancer Innovations & Healthcare index. The Index tracks the performance of publicly traded biotechnology, pharmaceutical and medical equipment companies that emphasize products and services focused on cancer detection and treatment. It employs a passive management approach to invest assets. The fund may also invest in foreign securities that are traded on a U.S. exchange or in a form of American Depository Receipts. The fund is nondiversified. |
| Last Dividend
| YFT_NOT_APPLICABLE_ABBREVIATION | | Last Cap Gain
(29-Dec-08):
| 0.59 | | Annual Holdings Turnover
| .00% | | Average for Category:
| 109.30% |
|
| Expense | CNCRX | Category
Avg | | Total Expense Ratio: | 5.13%
| 1.67% | | Max 12b1 Fee: | 0.25%
| N/A | | Max Front End Sales Load: | 5.50%
| 5.35% | | Max Deferred Sales Load: | %
| 2.88% | | 3 Yr Expense Projection*: |
$ 2,002 | $716 | | 5 Yr Expense Projection*: |
$ 2,966 | $1,069 | | 10 Yr Expense Projection*: |
$ 5,366 | $2,090 |
|
|
1.89% Nasdaq 
Profile
